新型冠状病毒Delta和Omicron变异株感染的儿童肝功能特征分析
DOI: 10.3969/j.issn.1001-5256.2022.09.023
Features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2
-
摘要:
目的 总结和分析新型冠状病毒(SARS-CoV-2)Delta与Omicron变异株感染儿童的肝功能特征。 方法 对2021年5月21日起广州医科大学附属市八医院收治的本土或入境SARS-CoV-2感染的儿童住院隔离期间肝功能检查结果进行总结分析,并比较SARS-CoV-2 Delta和Omicron变异株感染的儿童各临床资料以及肝损伤的构成比。计量资料两组间比较采用独立样本t检验或Mann-Whitney U检验;计数资料两组间比较采用χ2检验或Fisher’s精确检验。 结果 共纳入85例SARS-CoV-2感染的儿童,其中包括32例(37.6%)Delta和53例(62.4%)Omicron变异株感染者,两组患儿年龄、性别、身高、体质量和合并疾病比较,差异均无统计学意义(P值均>0.05)。SARS-CoV-2 Delta和Omicron变异株感染的儿童ALT、AST、ALP、GGT、TBil、Alb和ChE差异均无统计学意义(P值均>0.05);Omicron变异株感染的儿童其TBA水平显著高于Delta变异株感染的儿童(Z=-2.336,P=0.020)。但两组患儿TBA中位数均在正常范围内,且异常的TBA构成比在两组间比较,差异无统计学意义(P>0.05)。85例儿童中10例(11.8%)出现肝功能指标轻度升高,其中7例TBA水平升高,1例ALT水平升高,1例ALT和AST水平升高,1例ALP水平升高。对SARS-CoV-2 Delta和Omicron变异株感染的儿童肝损伤分析结果显示,两种SARS-CoV-2变异株感染所致肝损伤的构成比差异无统计学意义(6.3% vs 15.1%,χ2=0.691,P=0.406)。 结论 SARS-CoV-2 Delta和Omicron变异株感染的儿童近期肝损伤较轻,但其感染所致远期肝功能损伤的影响有待进一步评估。 Abstract:Objective To summarize and analyze the features of liver function in pediatric patients infected with Delta variant versus Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods In this study, an analysis was performed for the liver function test results of the locally transmitted or imported pediatric patients with SARS-CoV-2 infection during isolation who were admitted to Guangzhou Eighth People's Hospital, Guangzhou Medical University, since May 21, 2021, and the clinical data and the constituent ratio of liver injury were compared between the pediatric patients infected with Delta variant and those infected with Omicron variant. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. Results A total of 85 pediatric patients infected with SARS-CoV-2 were enrolled, among whom there were 32 (37.6%) pediatric patients infected with Delta variant and 53 (62.4%) pediatric patients infected with Omicron variant, and there were no significant differences between the two groups in age, sex, body height, body weight, and comorbidities (all P > 0.05). There were no significant differences between the two groups in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase, total bilirubin, albumin, and cholinesterase (all P > 0.05), and the pediatric patients infected with Omicron variant had a significantly higher level of total bile acid (TBA) than those infected with Delta variant (Z=-2.336, P=0.020). However, the median values of TBA were within the normal range and the ratios of abnormal TBA were no significant difference between the two groups (P > 0.05). Among the 85 pediatric patients, 10 (11.8%) had a mild increase in liver function parameters, among whom 7 had an increase in TBA, 1 had an increase in ALT, 1 had increases in ALT and AST, and 1 had an increase in ALP. The analysis of liver injury in the pediatric patients infected with Delta variant or Omicron variant showed that there was no significant difference in the constituent ratio of liver injury caused by the two variants (6.3% vs 15.1%, χ2=0.691, P=0.406). Conclusion Mild liver injury is observed in pediatric patients infected with Delta and Omicron variants of SARS-CoV-2, but further studies are needed to evaluate the long-term influence of such infection on liver function. -
Key words:
- SARS-CoV-2 /
- Liver Injury /
- Child
-
表 1 SARS-CoV-2 Delta和Omicron变异株感染的85例儿童一般资料分析
Table 1. Basic clinical data of 85 SARS-CoV-2 Delta and Omicron variant infected pediatric patients
项目 Delta变异株感染(n=32) Omicron变异株感染(n=53) 统计值 P值 年龄(岁) 8.0(3.3~11.0) 6.0(3.0~9.0) Z=-1.455 0.146 性别[例(%)] χ2=3.125 0.077 男 13(40.6) 32(60.4) 女 19(59.4) 21(39.6) 身高(cm) 0~5岁 92.3±13.3 94.3±14.6 t=-0.398 0.693 6~10岁 135.8±10.4 131.5±11.8 t=0.865 0.396 10岁以上 155.0±7.0 142.9±47.2 t=-1.528 0.129 体质量(kg) 0~5岁 14.6±3.8 14.8±5.2 t=-0.159 0.874 6~10岁 27.6±4.9 27.3±8.9 t=0.089 0.930 10岁以上 42.1±4.9 47.6±10.7 t=0.880 0.389 临床分型[例(%)] χ2=15.401 <0.001 无症状感染者 12(37.5) 8(15.1) 轻型 13(40.6) 43(81.1) 普通型 7(21.9) 2(3.8) 疫苗接种[例(%)] χ2=23.255 <0.001 是 1(3.1) 29(54.7) 否 31(96.9) 24(45.3) 合并疾病[例(%)] 0.241 G6PD缺乏症 0 4(7.5) 哮喘 1(3.1) 1(1.9) 乳糖不耐受 0 1(1.9) 巨趾症 1(3.1) 0 注:G6PD缺乏症,葡萄糖-6-磷酸脱氢酶缺乏症。 表 2 SARS-CoV-2 Delta和Omicron变异株感染的儿童肝功能指标比较
Table 2. Comparison of liver function tests between SARS-CoV-2 Delta and Omicron variant infected pediatric patients
肝功能指标 Delta变异株感染(n=32) Omicron变异株感染(n=53) Z值 P值 ALT(U/L) 11.1(9.2~15.3) 12.7(10.0~16.0) -1.339 0.181 AST(U/L) 24.1(17.8~29.6) 26.8(23.0~38.2) -1.824 0.068 TBA(μmol/L) 3.1(2.4~5.2) 5.0(3.0~7.6) -2.336 0.020 ALP(U/L) 232.5(206.5~285.0) 251.0(218.0~298.0) -1.034 0.301 GGT(U/L) 11.5(9.3~13.0) 10.0(7.0~12.0) -1.318 0.188 TBil(μmol/L) 5.1(3.7~6.3) 4.5(3.3~5.9) -0.272 0.768 Alb(g/L) 46.2(44.4~47.4) 45.3(43.7~47.0) -1.025 0.305 ChE(kU/L) 8.8(7.2~9.2) 8.8(8.1~10.1) -1.096 0.273 表 3 10例SARS-CoV-2感染致肝损伤的儿童各项肝功能指标的峰值
Table 3. Abnormal liver function tests in SARS-CoV-2 Delta and Omicron variant infected pediatric patients
患者 年龄 性别 毒株 ALT(U/L) AST(U/L) ALP(U/L) TBA(μmol/L) 病例1 6岁 男 Omicron 60.0 正常 正常 正常 病例2 7岁 男 Omicron 77.0 82.0 正常 正常 病例3 2岁5月龄 女 Delta 正常 正常 840.0 正常 病例4 5岁 女 Omicron 正常 正常 正常 13.3 病例5 1岁 男 Omicron 正常 正常 正常 15.7 病例6 7岁 女 Omicron 正常 正常 正常 16.6 病例7 1岁3月龄 女 Delta 正常 正常 正常 16.7 病例8 5岁 女 Omicron 正常 正常 正常 16.9 病例9 2岁 女 Omicron 正常 正常 正常 23.1 病例10 5岁 男 Omicron 正常 正常 正常 33.8 注:ALT正常值参考范围(1~12岁)12~45 U/L;AST正常值参考范围(3~9岁)15~50 U/L;ALP正常值参考范围(1~9岁)100~420 U/L;TBA正常值参考范围0~10 μmol/L。 -
[1] MARSH K, TAYLER R, POLLOCK L, et al. Investigation into cases of hepatitis of unknown aetiology among young children, Scotland, 1 January 2022 to 12 April 2022[J]. Euro Surveill, 2022, 27(15): 2200318. DOI: 10.2807/1560-7917.ES.2022.27.15.2200318. [2] National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 9)[J]. Inter J Epidemiol Infect Dis, 2022, 49(2): 73-80. DOI: 10.3760/cma.j.cn331340-20220325-00065.中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2): 73-80. DOI: 10.3760/cma.j.cn331340-20220325-00065. [3] American College of Clinical Pharmacy. Reference values for common laboratory tests[EB/OL]. https://www.accp.com/docs/sap/Lab_values_Table_PedSAP.pdf. [4] World Health Organization. Disease Outbreak News; Acute hepatitis of unknown aetiology-the United Kingdom of Great Britain and Northern Ireland (15 April 2022)[EB/OL]. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON368. [5] MA K, YANG ZY, CHEN T, et al. Pay close attention to the current characteristics and development trend of severe acute hepatitis with unknown etiology in children worldwide[J]. Natl Med J China, 2022, 102(20): 1429-1432. DOI: 10.3760/cma.j.cn112137-20220505-00986.马科, 杨中原, 陈韬, 等. 高度关注当前全球多国不明原因儿童严重急性肝炎的特征及发展动向[J]. 中华医学杂志, 2022, 102(20): 1429-1432. DOI: 10.3760/cma.j.cn112137-20220505-00986. [6] RONAN BA, AGRWAL N, CAREY EJ, et al. Fulminant hepatitis due to human adenovirus[J]. Infection, 2014, 42(1): 105-111. DOI: 10.1007/s15010-013-0527-7. [7] KAWASHIMA N, MURAMATSU H, OKUNO Y, et al. Fulminant adenovirus hepatitis after hematopoietic stem cell transplant: Retrospective real-time PCR analysis for adenovirus DNA in two cases[J]. J Infect Chemother, 2015, 21(12): 857-863. DOI: 10.1016/j.jiac.2015.08.018. [8] BOETTLER T, CSERNALABICS B, SALIÉ H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis[J]. J Hepatol, 2022. DOI: 10.1016/j.jhep.2022.03.040.[Online ahead of print] [9] ZHU Z, MAO NY, ZHANG Y, et al. Consideration on the emerging of severe acute hepatitis cases with of unknown etiology in children worldwide[J]. Chin J Prevent Med, 2022, 56(6): 679-681. DOI: 10.3760/cma.j.cn112150-20220427-00423.朱贞, 毛乃颖, 张燕, 等. 对当前全球部分国家出现的不明原因儿童急性严重肝炎病例的思考[J]. 中华预防医学杂志, 2022, 56(6): 679-681. DOI: 10.3760/cma.j.cn112150-20220427-00423. [10] LIN HW, LEI Y, CHEN BB, et al. Clinical features of patients with severe acute respiratory syndrome coronavirus 2 Delta variant infection and abnormal liver function in Guangdong Province, China[J]. J Clin Hepatol, 2022, 38(3): 582-586. DOI: 10.3969/j.issn.1001-5256.2022.03.017.林浩炜, 雷燕, 陈彬彬, 等. 广东地区新型冠状病毒Delta变异株感染并发肝功能异常患者的临床特征分析[J]. 临床肝胆病杂志, 2022, 38(3): 582-586. DOI: 10.3969/j.issn.1001-5256.2022.03.017. [11] EKPANYAPONG S, BUNCHORNTAVAKUL C, REDDY KR. COVID-19 and the liver: Lessons learnt from the EAST and the WEST, a year later[J]. J Viral Hepat, 2022, 29(1): 4-20. DOI: 10.1111/jvh.13590. [12] HUANG YK, LI YJ, LI B, et al. Dysregulated liver function in SARS-CoV-2 infection: Current understanding and perspectives[J]. World J Gastroenterol, 2021, 27(27): 4358-4370. DOI: 10.3748/wjg.v27.i27.4358. [13] VIANA R, MOYO S, AMOAKO DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa[J]. Nature, 2022, 603(7902): 679-686. DOI: 10.1038/s41586-022-04411-y. [14] ADAM D. What scientists know about new, fast-spreading coronavirus variants[J]. Nature, 2021, 594(7861): 19-20. DOI: 10.1038/d41586-021-01390-4. [15] DENG H, LIN H, MAI Y, et al. Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients[J]. Eur J Gastroenterol Hepatol, 2022. DOI: 10.1097/MEG.0000000000002381.[Online ahead of print] [16] CHAI XQ, HU LF, ZHANG Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection[J]. bioRxiv, 2020. DOI: 10.1101/2020.02.03.931766.[Online ahead of print] [17] BRODIN P, ARDITI M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens[J]. Lancet Gastroenterol Hepatol, 2022, 7(7): 594-595. DOI: 10.1016/S2468-1253(22)00166-2.
计量
- 文章访问数: 335
- HTML全文浏览量: 162
- PDF下载量: 26
- 被引次数: 0